November 05, 2009
Orphan drug designation granted to Abraxane for pancreatic cancer and Stage IIB-IV melanomaAbraxis BioScience was granted orphan drug designation by the FDA for its drug candidate, Abraxane for Injectable Suspension (paclitaxel albumin [human]-bound particles for injectable suspension) for the treatment of pancreatic cancer and Stage IIB-IV melanoma.
Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer that combines paclitaxel with albumin, a naturally-occurring human protein. By wrapping albumin around the active drug, Abraxane can be administered to patients at higher doses, delivering higher concentrations of paclitaxel to the tumor site than solvent-based paclitaxel.
For more information call (800) 564-0216 or visit www.abraxisbio.com.